Ligand Pharmaceuticals
LGND
243 hedge funds and large institutions have $1.81B invested in Ligand Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 98 increasing their positions, 53 reducing their positions, and 28 closing their positions.
535% more call options, than puts
Call options by funds: $5.91M | Put options by funds: $931K
85% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 53
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
25% more capital invested
Capital invested by funds: $1.45B → $1.81B (+$360M)
3% more funds holding
Funds holding: 235 → 243 (+8)
3.15% more ownership
Funds ownership: 96.07% → 99.22% (+3.1%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.9M |
| 2 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$11.9M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$11.5M |
| 4 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$10.1M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$7.98M |
| 2 |
DMKJ
David M. Knott Jr
|
-$7.16M |
| 3 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
-$3.35M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.75M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.21M |
LGND Hedge Fund Activity: Q3 2024 in Review
243 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2024, worth a combined $1.81B — up 25% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new LGND positions and 28 closed out — a net gain of 9 holders — while 98 added to existing stakes and 53 trimmed.
The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was Macquarie Group, cutting an estimated $7.98M.
- 243 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2024, up from 235 in Q2 2024.
- Funds reported $1.81B of Ligand Pharmaceuticals stock for Q3 2024, up 25% quarter-over-quarter.
- 37 funds opened new Ligand Pharmaceuticals positions in Q3 2024 and 28 closed out, a net change of +9 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2024 was BlackRock, an estimated $12.9M added.
- The largest Ligand Pharmaceuticals seller in Q3 2024 was Macquarie Group, an estimated $7.98M sold.
Based on aggregated 13F filings for Q3 2024.